Eupraxia Pharmaceuticals Reports Results With 8mg Dose In RESOLVE Trial; Patients In Cohort 9 Experienced The Largest Improvements In Tissue Health Outcomes And Eosinophil Reduction Observed To Date; Expands Phase 2b EP-104GI Study And Plans New GI Indication Trial In 2026

Author: Benzinga Newsdesk | September 29, 2025 04:03pm

• Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial.
• Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.
• RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.
• Eupraxia intends to expand the EP-104GI development program, including increasing the number of patients in the Phase 2b portion of RESOLVE from 60 to at least 120 patients.
• Eupraxia intends to initiate a clinical trial for an additional market-expanding GI indication in the first half of 2026.
• Eupraxia will host a webinar on October 1st at 8am PDT to provide additional information. The live webinar is available at: https://lifescievents.com/event/fk30t7wg2n/

VICTORIA, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today provided an operational update on the development of EP-104GI, including reporting data from patients in Cohort 9 of the dose escalation portion of the RESOLVE trial, the first time that patients received an 8mg dose per injection.

Posted In: EPRX TSX:EPRX